Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01831765 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,290
- Enrollment target
NCT01831765: Completed Phase 3 study, sponsored by Novo Nordisk A/S.
NCT01831765 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 1,290 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (67% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01831765, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,290 participants
- Enrollment target
Study Summary
This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of FIAsp (faster-acting insulin aspart) compared to insulin aspart, both in combination with insulin detemir in adults with type 1 diabetes. This trial consists of two periods: a 26 week treatment period followed by a 26 week additional treatment period.
Primary Outcome
Change from baseline in HbA1c after 26 weeks of randomised treatment.
Interventions
- DRUG insulin aspart
- DRUG insulin detemir
- DRUG Faster-acting insulin aspart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,290 participants |
| Start Date | 2013-08-26 |
| Est. Completion | 2015-06-11 |
| Phase | Phase 3 |
What the finished NCT01831765 record still lists
NCT01831765 is an interventional study that assigns participants to a tested intervention. Its 1,290 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (67% higher).
The record links to 0 conditions, and to 3 interventions - of which insulin aspart is the first listed.
NCT01831765 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01831765 about?
NCT01831765 is a clinical study titled "Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes". This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of FIAsp (faster-acting insulin aspart) compared to insulin aspart, both in combination with insulin detemir in adults with type 1 diabetes. This trial consists of two...
What is the current status of trial NCT01831765?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,290 participants. The study started on 2013-08-26. Estimated completion is 2015-06-11.
What interventions are being tested in trial NCT01831765?
The interventions under investigation include: insulin aspart (DRUG), insulin detemir (DRUG), Faster-acting insulin aspart (DRUG).
Who is sponsoring clinical trial NCT01831765?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01831765's enrollment target sits among peer trials
1,290 196th of 2000 higher than 1,804 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05595642 · 1,290 participants · Phase 3
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
- NCT05812807 · 1,295 participants · Phase 3
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
- NCT06626022 · 1,284 participants · Phase 3
Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
- NCT04474223 · 1,300 participants · Phase 3
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI